Filtered By:
Specialty: International Medicine & Public Health
Condition: Bleeding
This page shows you your search results in order of date. This is page number 18.
Order by Relevance | Date
Total 274 results found since Jan 2013.
Effectiveness And Safety Of Reduced Dose Non-Vitamin K Antagonist Oral Anticoagulants In Patients Without Severe Renal Impairment
The introduction of non-vitamin K antagonist oral anticoagulants (NOACs) has been a major advance for stroke prevention in atrial fibrillation. Because NOACs have significant renal clearance, dose reduction is needed in patients with severe kidney disease. However, some physicians may prescribe reduced-dose NOACs to patients with relatively good renal function due to the concerns over the bleeding risk. We sought to investigate the use and clinical outcomes of reduced-dose NOACs in patients without severe renal impairment.
Source: Value in Health - April 30, 2016 Category: Global & Universal Authors: X. Yao, N.D. Shah, L.R. Sangaralingham, B.J. Gersh Source Type: research
Apixaban In Patients With Atrial Fibrillation: Patient Characteristics Of The Latin America Cohort From A Multinational Clinical Trial
Patients with Atrial fibrillation (AF), have a five-fold increase in the risk of stroke. Treatment for AF include stroke prevention therapy. Vitamin K antagonists (VKAs) have shown to prevent stroke in AF patients. Apixaban, a novel oral direct factor Xa inhibitor was studied in AF patients whom VKA therapy was unsuitable. Apixaban demonstrated clinical benefit in stroke or systemic embolism reduction without impacting the risk of major bleeding or intracranial hemorrhage. Patient characteristics of the Latin America (LA) cohort and overall population are presented.
Source: Value in Health - October 23, 2015 Category: Global & Universal Authors: A Avezum, MC Bahit, JA Hermosillo, FL Zanetti, P Perafan, A Juarez-Garcia, C Vulcano, LA Cubillos, BM Korenblat Donato Source Type: research
Relationship of Time in Therapeutic Range (Ttr) with Bleeding and Stroke Incidences of Warfarinised Patients with Pulmonary Embolism in a Tertiary Hospital in Malaysia
This study aims to compare time in therapeutic range (TTR) of warfarin in patients with pulmonary embolism with bleeding and stroke and determine reasons of INR falling out of range.
Source: Value in Health - October 23, 2015 Category: Global & Universal Authors: N Sudirman, S Shaharuddin, CM Long, R Hashim, HH Zulkifly, SS Kasim, CW Lim Source Type: research
Preliminary Study of Safety and Efficacy of Warfarin Versus Dabigatran in Atrial Fibrillation Patients in a Tertiary Hospital in Malaysia
This study aims to compare the pattern of anticoagulants used and to assess their safety and efficacy by evaluating bleeding and stroke occurrences in both groups.
Source: Value in Health - October 23, 2015 Category: Global & Universal Authors: M Mohd Hajiri, S Shaharuddin, CM Long, R Hashim, HH Zulkifly, SS Kasim, CW Lim Source Type: research
Co-Administration of Proton Pump Inhibitors in Chronic Aspirin Users and the Risk of Adverse Cardiovascular Events: a Population-Based Cohort Study
This study investigated the effect of co-administration of PPIs in aspirin users with a first acute myocardial infarction (AMI) or stroke on the risk of recurrence of such a CV event.
Source: Value in Health - October 23, 2015 Category: Global & Universal Authors: A Tran-Duy, FH Vanmolkot, PC Souverein, AW Hoes, A de Boer, CD Stehower, NJ de Wit, MA Joore, F de Vries Source Type: research
Resource Utilisation And Bleeding Events During Anticoagulation Treatment: Real-World Findings From England
This study aimed to estimate the association between healthcare resource use and subsequent bleeding in NVAF patients prescribed VKA in England.
Source: Value in Health - October 23, 2015 Category: Global & Universal Authors: S Lister, C Lefevre, I Menown, R Alikhan, L Lacoin, A Bird, M You, E Ridha, D Evans Source Type: research
Accreditation and improvement in process quality of care: a nationwide study
Conclusions
Participating in accreditation was not associated with larger improvement in performance measures for acute stroke, heart failure or ulcer.
Source: International Journal for Quality in Health Care - September 28, 2015 Category: Global & Universal Authors: Bogh, S. B., Falstie-Jensen, A. M., Bartels, P., Hollnagel, E., Johnsen, S. P. Tags: Papers Source Type: research
WATCHMAN device gives patients alternative to blood thinners and reduces stroke risk
(MedStar Washington Hospital Center) MedStar Heart & Vascular Institute at MedStar Washington Hospital Center was the first in the Washington metropolitan region to implant the newly approved WATCHMAN Device. The new device is designed to prevent stroke in high-risk patients with atrial fibrillation who are seeking an alternative to blood-thinning medication. Blood thinners are effective in stroke risk reductions for A-fib patients, but many cannot tolerate these drugs because of the risk of bleeding. Now, there's a new option.
Source: EurekAlert! - Medicine and Health - July 2, 2015 Category: Global & Universal Source Type: news
Estimation of the cost-effectiveness of apixaban versus vitamin K antagonists in the management of atrial fibrillation in Argentina
Abstract
Apixaban, a novel oral anticoagulant which has been approved for the prevention of stroke and systemic embolism in non-valvular atrial fibrillation, reduces both ischemic and haemorrhagic stroke and produces fewer bleedings than vitamin K antagonist warfarin. These clinical results lead to a decrease in health care resource utilization and, therefore, have a positive impact on health economics of atrial fibrillation. The cost-effectiveness of apixaban has been assessed in a variety of clinical settings and countries. However, data from emergent markets, as is the case of Argentina, are still scarce.
...
Source: Health Economics Review - June 26, 2015 Category: Global & Universal Source Type: research
Comparing Patient and Physician Risk Tolerance for Bleeding Events Associated with Anticoagulants in Atrial Fibrillation—evidence from the United States and Japan
Conclusions Overall, preferences for anticoagulant benefits and risks were not statistically different between patients and physicians in the United States, nor were there differences in preferences for different stroke risks between physicians in the United States and Japan; however, preferences were different between patients and physicians in Japan.
Source: Value in Health Regional Issues - May 16, 2015 Category: Global & Universal Source Type: research
Cost effectiveness of left atrial appendage closure versus Warfarin for stroke risk reduction in non-valvular Atrial Fibrillation in CMS patients
Stroke is the most severe and debilitating consequence of atrial fibrillation (AF), with many patients ranking the resultant disability as worse than death. Warfarin, the established first-line therapy, is effective at reducing ischemic stroke, but is associated with increased bleeding risk and lower quality of life (QoL). Left atrial appendage closure (LAAC) with the Watchman Device has been found to be superior to warfarin at reducing risk of stroke in AF patients. This analysis sought to assess the cost effectiveness of LAAC versus warfarin for stroke prevention in non-valvular AF from the perspective of the US Centers ...
Source: Value in Health - May 1, 2015 Category: Global & Universal Authors: V. Reddy, R. Akehurst, S.L. Amorosi, S. Armstrong, S. Beard, C. Knight, C. Taggart, D. Holmes Source Type: research
Trial of bivalirudin during angioplasty reports mixed results
(American College of Cardiology) Patients with acute coronary syndrome undergoing angioplasty who received the anticoagulant drug bivalirudin did not show significant improvements in either of two co-primary endpoints -- a composite of rate of death, heart attack or stroke at 30 days, or a composite of those events plus major bleeding -- as compared to patients receiving standard anticoagulation therapy, according to a study presented at the American College of Cardiology's 64th Annual Scientific Session.
Source: EurekAlert! - Medicine and Health - March 16, 2015 Category: Global & Universal Source Type: news
Treatment Patterns And Quality Of Life Of Patients With Non-Valvular Atrial Fibrillation: An Experience Of A Tertiary Health Care Centers (Treq-Af Study)
This study aimed to determine anti-coagulant treatment patterns and stroke- and bleeding-related risk factors and to evaluate quality of life (QoL) in non-valvular atrial fibrillation (NVAF) patients.
Source: Value in Health - November 1, 2014 Category: Global & Universal Authors: B. Ozin, K. Aytemir, O. Arslan, T. Ozcan, M. Kanadasi, M. Demir, M. Gokce, M.M. Sucu, M. Ozdemir, Z. Yigit, M.F. Yavuzkir, A. Oto Source Type: research
Relation Of The Time In Therapeutic Range (Ttr) Of Warfarin To Bleeding Incidences In Patients With Atrial Fibrillation
This study aims to compare and establish relation of time in therapeutic range (TTR) of warfarin in patients with atrial fibrillation in the first 6 months and 6 month thereafter of anticoagulation therapy.
Source: Value in Health - November 1, 2014 Category: Global & Universal Authors: M.A.S. Jasmi, M.N. Mazlan, S. Shaharuddin, H.H. Zulkifly, C.M. Long, R. Hashim, Wahab M.S. Abdul Source Type: research
Predicting which stroke patients will be helped -- or harmed -- by clot-busting treatment
(Johns Hopkins Medicine) Johns Hopkins researchers say they have developed a technique that can predict -- with 95 percent accuracy -- which stroke victims will benefit from intravenous, clot-busting drugs and which will suffer dangerous and potentially lethal bleeding in the brain.
Source: EurekAlert! - Medicine and Health - May 19, 2014 Category: Global & Universal Source Type: news
